|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Discovery Biology Laboratory, Department of Pharmacology, Monash University, Victoria, Australia (A.C., P.M.S.); and Department of Pharmacology, University of Melbourne, Victoria, Australia (A.A.L.)
This study investigated the reciprocal cross-interactions between two distinct allosteric sites on the M4 muscarinic acetylcholine receptor (mAChR) in the absence or presence of different orthosteric ligands. Initial studies revealed that two novel benzimidazole allosteric modulators, 17-
-hydroxy-17-
-ethy nyl-delta(4)-androstano[3,2-b]pyrimido[1,2-a]benzimidazole (WIN 62,577) and 17-
-hydroxy-17-
-ethynyl-5-
-androstano[3,2-b]pyrimido[1,2-a]benzimidazole (WIN 51,708), exhibited different degrees of positive, negative, or close-to-neutral cooperativity with the orthosteric site on M1 or M4 mAChRs, depending on the chemical nature of the orthosteric radioligand that was used [[3H]N-methylscopolamine ([3H]NMS) versus [3H]quinuclidinylbenzilate ([3H]QNB)]. The largest window for observing an effect (negative cooperativity) was noted for the combination of WIN 62,577 and [3H]QNB at the M4 mAChR. Experiments involving the combination of these two ligands with unlabeled agonists [acetylcholine, 4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium (McN-A-343), or xanomeline] revealed low degrees of negative cooperativity between WIN 62,577 and each agonist, whereas stronger negative cooperativity was observed against atropine. It is interesting that when these experiments were repeated using the prototypical modulators heptane-1,7-bis-(dimethyl-3'-phthalimidopropyl)-ammonium bromide (C7/3-phth), alcuronium, or brucine (which act at a separate allosteric site), WIN 62,577 exhibited negative cooperativity with each modulator when the orthosteric site was unoccupied, but this switched to neutral cooperativity when the receptor was occupied by [3H]QNB. Dissociation kinetic experiments using [3H]NMS and combination of C7/3-phth with WIN 62,577 also provided evidence for neutral cooperativity between the two allosteric sites when the orthosteric site is occupied. Together, these results provide insight into the nature of the interaction between two distinct allosteric sites on the M4 mAChR and how this interaction is perturbed upon occupancy of the orthosteric site.
Received for publication March 20, 2006.
Accepted for publication May 18, 2006.
Address correspondence to: Dr. Arthur Christopoulos, Drug Discovery Biology Laboratory, Department of Pharmacology, Building 13E, Monash University, Clayton, 3800, Victoria, Australia. E-mail: arthur.christopoulos{at}med.monash.edu.au
This article has been cited by other articles:
![]() |
K. J. Mansfield, J. J. Chandran, K. J. Vaux, R. J. Millard, A. Christopoulos, F. J. Mitchelson, and E. Burcher Comparison of Receptor Binding Characteristics of Commonly Used Muscarinic Antagonists in Human Bladder Detrusor and Mucosa J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 893 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Heitman, K. Ye, J. Oosterom, and A. P. IJzerman Amiloride Derivatives and a Nonpeptidic Antagonist Bind at Two Distinct Allosteric Sites in the Human Gonadotropin-Releasing Hormone Receptor Mol. Pharmacol., June 1, 2008; 73(6): 1808 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Goodwin, E. C. Hulme, C. J. Langmead, and B. G. Tehan Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands Mol. Pharmacol., December 1, 2007; 72(6): 1484 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476. [Abstract] [Full Text] [PDF] |
||||